首页> 外文期刊>MicroRNA >Circulating miRNA-21 and miRNA-23a Expression Signature as Potential Biomarkers for Early Detection of Non-Small-Cell Lung Cancer
【24h】

Circulating miRNA-21 and miRNA-23a Expression Signature as Potential Biomarkers for Early Detection of Non-Small-Cell Lung Cancer

机译:循环miRNA-21和miRNA-23a表达签名作为早期检测非小细胞肺癌的潜在生物标志物

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Background and Aim: Lung Cancer (LC) is a major cancer killer worldwide, and 5-yr survival is extremely poor (<15%), accentuating the need for more effective diagnostic and therapeutic strategies. Studies have shown cell-free microRNAs (miRNAs) circulating in the serum and plasma with specific expression in cancer, indicating the potential of using miRNAs as biomarkers for cancer diagnosis and therapy. This study aimed to identify differentially-expressed two miRNAs in the plasma of Non-Small Cell Lung Cancer (NSCLC) patients that might be a clinically useful tool for lung cancer early detection. miRNA-21 is one of the most abundant oncomirs. miRNA-23a functions as an oncogene in several human cancers, however,its clinical value has not been investigated in NSCLC. Materials and Methods: A case-control study was conducted in Assiut University Hospital, Egypt, from 2017 to 2018. Plasma samples were obtained from 45 NSCLC patients. The expression level of miR-21 and miRNA-23a was detected by qRT-PCR and compared to 40 healthy control subjects. The relation between both miRNAs and clinicopathological parameters was evaluated. Results: The expression level of miR-21 and miRNA-23a was significantly up-regulated (36.9 ± 18.7 vs. 1.12 ± 0.84 and 24.7 ± 19.09 vs. 1.16 ± 0.45) in NSCLC compared to matched controls (P<0.000leach). There was a significant difference in the level of plasma miRNA-21 and miRNA-23a expression between the different grades of the disease (P = 0.032 and P = 0.001, respectively). The plasma miRNA-21 and miRNA-23a levels in the lung cancer patients with distant metastasis (n =20) were significantly higher than those in the patients without metastasis (n = 25) (P<0.0001 each), the expression of miR-21 and miRNA-23a was significantly associated with tumor size (P = 0.001,P = 0.0001,respectively), but not significantly related to lymph node metastasis (P = 0.687 and 0.696,respectively). A positive correlation was observed between miRNA-21 and miRNA-23a
机译:背景和目的:肺癌(LC)是全世界的主要癌症杀手,5 yr生存率极差(<15%),巧妙地需要更有效的诊断和治疗策略。研究表明,在血清和血浆中循环的无细胞microRNA(miRNA),具有癌症的特异性表达,表明使用MiRNA作为癌症诊断和治疗的生物标志物的潜力。该研究旨在在非小细胞肺癌(NSCLC)血浆中鉴定差异表达的两种miRNA,这可能是肺癌早期检测的临床有用的工具。 miRNA-21是最丰富的牛皮虫之一。 miRNA-23a在几种人类癌症中用作癌基因,然而,在NSCLC中尚未研究其临床价值。材料与方法:从2017年至2018年在埃及Assiut大学医院进行了案例对照研究。从45例NSCLC患者获得血浆样品。通过QRT-PCR检测miR-21和miRNA-23a的表达水平,并与40个健康对照受试者进行比较。评估miRNA和临床病理学参数之间的关系。结果:与匹配的对照(P <0.000展示)相比,MiR-21和miRNA-23a的表达水平显着上调(36.9±18.7和1.12±0.84和24.7±19.09〜1.16±0.45)。血浆miRNA-21和MiRNA-23a表达的不同等级之间的表达差异有显着差异(P = 0.032和P = 0.001)。肺癌患者的血浆miRNA-21和MiRNA-23a水平远处转移(n = 20)显着高于没有转移的患者(n = 25)(每次p <0.0001),表达miR- 21和miRNA-23a与肿瘤大小有显着相关(分别为p = 0.001,p = 0.0001),但与淋巴结转移显着相关(分别为p = 0.687和0.696)。 miRNA-21和miRNA-23a之间观察到阳性相关性

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号